Beta Bionics, Inc. Stock Price, News & Analysis

Beta Bionics (BBNX) reported strong Q1 2025 financial results and raised its annual guidance. Net sales reached $17.6 million, up 36% year-over-year, driven by growth in both DME and PBP channels. The company's installed customer base grew 291% to 19,151 users, with 3,853 new patient starts (48% increase). Despite revenue growth, the company reported increased losses with operating loss of $18.6 million and net loss of $28.7 million. Beta Bionics completed an IPO raising $206 million and secured Prime Therapeutics coverage for its iLet Bionic Pancreas. The company raised its 2025 guidance, now expecting revenue of $82-87 million and PBP channel patient starts of 22-25%. The company maintains $295.5 million in cash and investments.

Beta Bionics (BBNX), a company focused on diabetes management solutions, has announced its participation in the upcoming Bank of America Securities Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2025, at 12:35 PM ET (9:35 AM PT) in Las Vegas. Interested parties can access the live audio webcast through the company's investor relations website under the "Events & Presentations" section at investors.betabionics.com. The presentation recording will be archived on the website for future viewing.

Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, has scheduled the release of its first quarter 2025 financial results for Tuesday, May 6, 2025, after market close.

The company will host a conference call and simultaneous webcast at 4:30 PM Eastern Time (1:30 PM Pacific Time) on the same day. Investors can access the live call by dialing (888) 596-4144 with passcode 8363701. The webcast will be available in the Investors—Events & Presentations section of the company's website and will be archived for future viewing.

Beta Bionics (Nasdaq: BBNX) has announced an upcoming investor event scheduled for June 22, 2025, in Chicago, coinciding with the 85th Scientific Sessions of the American Diabetes Association. The event will run from 7:00 AM to 8:30 AM Central Time.

The presentation will feature:

• Commercial and financial performance updates
• Demonstration of new patch pump development
• Review of adaptive closed-loop algorithm
• Presentation of new real-world clinical data

The event will be accessible via live webcast through the company's investor relations website. In-person attendance requires registration through Beta Bionics' IR representative. A replay of the webcast and presentation materials will be available on the company website after the event.

Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, has appointed Gerard Michel as an independent board director effective March 26, 2025. Michel, currently CEO of Delcath Systems (Nasdaq: DCTH), brings over 30 years of pharmaceutical and medical technology industry experience.

Michel's extensive background includes serving as CFO at Vericel , CFO and VP of Corporate Development at Biodel Inc. (2007-2014), and similar roles at NPS Pharmaceuticals (2002-2007). He previously held positions at Booz Allen and worked in commercial roles at Lederle Labs and Wyeth Labs.

Michel holds an M.S. in Microbiology from the University of Rochester School of Medicine, an M.B.A. from Simon School of Business, and dual B.S. degrees in Biology and Geology.

Beta Bionics (NASDAQ: BBNX) reported strong Q4 and full-year 2024 financial results. Q4 net sales reached $20.4M, up 145% YoY, with DME channel sales of $18.1M (+127%) and PBP channel sales of $2.4M (+491%). The installed customer base grew to 15,298 users (+564%).

Full-year 2024 showed net sales of $65.1M (+443% YoY), with DME channel sales of $58.8M and PBP channel sales of $6.3M. The company completed an IPO raising $206M and launched the Color iLet Bionic Pancreas with FreeStyle Libre 3 Plus integration.

For 2025 guidance, Beta Bionics expects revenue of $80-85M, with over 20% of new patient starts through PBP channel and gross margin of at least 50%. The company ended 2024 with $103.6M in cash and equivalents.

Beta Bionics (NASDAQ: BBNX), a leader in advanced diabetes management solutions, has scheduled the release of its Q4 and full year 2024 financial results for March 25, 2025, after market close.

The company will host a conference call and webcast at 4:30 PM ET (1:30 PM PT) on the same day to discuss the financial performance. Investors can access the webcast through the company's investor relations website, and a replay will be available afterward.

Beta Bionics (Nasdaq: BBNX) has successfully completed its upsized initial public offering, raising $234.6 million. The company sold 13,800,000 shares of common stock at $17.00 per share, including the full exercise of the underwriters' option for 1,800,000 additional shares. The IPO generated approximately $212.1 million in gross proceeds for Beta Bionics before expenses.

Additionally, the company conducted a concurrent private placement of 1,000,000 shares at the IPO price to an existing investor, bringing total gross proceeds to approximately $229.1 million. Trading began on the Nasdaq Global Market on January 30, 2025, under the ticker symbol 'BBNX'. The offering was led by BofA Securities, Piper Sandler, and Leerink Partners as lead bookrunners, with Stifel as bookrunner and Lake Street Capital Markets as co-manager.

Beta Bionics has announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at $17.00 per share, expecting to raise gross proceeds of $204.0 million. The company's shares will begin trading on the Nasdaq Global Market on January 30, 2025, under the ticker symbol BBNX.

The underwriters have a 30-day option to purchase up to an additional 1,800,000 shares. Additionally, Beta Bionics has agreed to sell 1,000,000 shares in a concurrent private placement at the same price, bringing the total potential gross proceeds to $221.0 million before expenses.

The offering is expected to close on January 31, 2025. BofA Securities, Piper Sandler, and Leerink Partners are acting as lead bookrunners, with Stifel as bookrunner and Lake Street Capital Markets as co-manager.